PIK3CA and breast carcinoma: Despite the pre-clinical evidence that PIK3CA is an oncogene, results on the relation between the PIK3CA mutation and outcomes are inconsistent in clinical studies, demonstrating worse outcomes in breast cancer patients with PIK3CA mutations, no differences in outcomes by mutation status and better outcomes for HR positive breast cancer with PIK3CA mutations recently [27–29].